menu
menu
The complimentary Biomarker Testing Navigation certificate program delivers a comprehensive, modular learning experience designed to strengthen the role of laboratory professionals in cancer biomarker testing and precision medicine. Developed by experts with deep experience across clinical, laboratory, and diagnostic settings, the certificate program offers practical insights into cancer biomarker workflows, interdisciplinary collaboration, and diagnostic stewardship.
Designed for laboratory professionals committed to advancing precision cancer care, the complimentary Biomarker Testing Navigation Certificate Program provides structured education across key domains of cancer biomarker testing. The certificate program features six core modules and five electives, allowing learners to tailor their education while ensuring mastery of essential competencies.
This complimentary certificate program offers up to 11 CMLE credits. Explore the Biomarker Testing Navigation Certificate Program and become a champion for cancer biomarker testing navigation today.
The Biomarker Testing Navigation certificate program is supported by a sponsorship from AstraZeneca.
This Playbook provides practical insights for pathologists and laboratory professionals who are working to improve how they perform HER2 testing in breast cancer and how they are navigating some of the challenges around reporting HER2-low and HER2-ultralow results.
The Playbook provides 1CME/1CMLE
Accurate classification of HER2 status in breast cancer is essential for determining the most effective treatment strategies. This infographic highlights some key concepts of HER2-low and HER2-ultralow breast cancer.
These activities are supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.
This new series of case-based microlearning courses are designed to help pathologists and laboratory professionals increase their knowledge, skills, and competence in applying practice- changing updates regarding HER2-low and HER2-ultralow advanced breast cancer.
This is the first of three activities and focuses on HER2 classification, tracking, and reporting considerations for HER2 IHC testing and interpretations in HER2-low breast cancers.
In the second portion of this three-part activity we focus on the emerging science of HER2-low and HER2-ultralow then go into current treatment for HER2-low and HER2-ultralow patients.
In this final part of the three activities, the focus is on reproducibility of testing and clinical significance of HER2-low and HER2-ultralow.
This microlearning series is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.
This microlearning course is designed to help pathologists, laboratory professionals, and other members of the cancer care team gain an understanding of emerging research in pan-tumor HER2 testing and of treatment options based on HER2 results. A particular focus of this activity is the DESTINY-Pan Tumor02 study and the latest evidence regarding HER2 testing, scoring and reporting. The microlearning design of this activity allows for a brief and focused exploration of this topic.
This microlearning course is designed to help pathologists, laboratory professionals, and other members of the cancer care team gain an understanding of emerging research in HER2-directed therapies in gynecologic cancers and of treatment options based on HER2 results. A particular focus of this activity is the DESTINY-PanTumor02 study and the latest evidence regarding HER2 testing, scoring and reporting in gynecologic cancers. The microlearning design of this activity allows for a brief and focused exploration of this topic.
This microlearning course is designed to help pathologists, laboratory professionals, and other members of the cancer care team gain an understanding of emerging research in pan-tumor HER2 testing in patients with advanced solid tumors and of treatment options based on HER2 results.
These activities are conducted in partnership with Q Synthesis, Society for Gynecological Oncology, and are supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.